Margaret K. Callahan
A5011114578- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- T-cell and B-cell Immunology
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Biosimilars and Bioanalytical Methods
- Advanced Breast Cancer Therapies
- Bladder and Urothelial Cancer Treatments
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- Cytokine Signaling Pathways and Interactions
- Colorectal Cancer Treatments and Studies
- Computational Drug Discovery Methods
- Synthesis and biological activity
- Single-cell and spatial transcriptomics
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Heat shock proteins research
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Wildlife Ecology and Conservation
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2015-2024
University of Connecticut
2002-2024
Gallipoli Medical Research Foundation
2024
Princess Alexandra Hospital
2024
Greenslopes Private Hospital
2024
Kettering University
2015-2023
Parker Institute for Cancer Immunotherapy
2018-2023
Wildlife Science Center
1996-2023
Weill Cornell Medicine
2022-2023
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] have been shown to complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or plus was compared with patients
Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than alone phase 3 trial involving patients advanced melanoma. We now report 3-year overall outcomes this trial.
In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase trial. On basis of their distinct immunologic mechanisms action supportive preclinical data, we conducted trial combined advanced melanoma.We administered intravenous doses every 3 weeks for doses, followed by alone (concurrent regimen). The treatment was...
With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for support tool that distills the implications associated with specific mutation events into standardized and easily interpretable format. To this end, we developed OncoKB, expert-guided precision oncology knowledge base.
The abscopal effect is a phenomenon in which local radiotherapy associated with the regression of metastatic cancer at distance from irradiated site. may be mediated by activation immune system. Ipilimumab monoclonal antibody that inhibits an immunologic checkpoint on T cells, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). We report case patient melanoma treated ipilimumab and radiotherapy. Temporal associations were noted: tumor shrinkage responses to cancer-testis NY-ESO-1, changes...
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, Melanoma...
Purpose Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab outside of clinical trials to determine the frequency use systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα) therapy effect these therapies on overall survival (OS) time failure (TTF). Patients Methods retrospectively medical records patients melanoma who had received between...
Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing examine non-small-cell cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. TMB was independent PD-L1 expression the strongest feature associated efficacy multivariable analysis....
Abstract The composition of the intestinal microbiota influences development inflammatory disorders. However, associating diseases with specific microbial members is challenging, because clinically detectable inflammation and its treatment can alter microbiota’s composition. Immunologic checkpoint blockade ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, associated new-onset, immune-mediated colitis. Here we conduct prospective...
CTLA-4 blocking antibody induces secondary hypophysitis by binding to antigen and initiating a type II hypersensitivity reaction.
Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load improved clinical outcomes platinum-treated metastatic urothelial carcinoma. We examined the relationship between DDR alterations to PD-1/PD-L1 blockade. Methods Detailed demographic, treatment response, long-term outcome data were collected on patients carcinoma treated atezolizumab or nivolumab who had targeted exon sequencing performed pre-immunotherapy tumor specimens. Presence...
Abstract Combination therapy concurrently targeting PD-1 and CTLA-4 immune checkpoints leads to remarkable antitumor effects. Although both dampen the T cell activation, in vivo effects of these drugs humans remain be clearly defined. To better understand biologic therapy, we analyzed blood/tumor tissue from 45 patients undergoing single or combination checkpoint blockade. We show that blockade CTLA-4, PD-1, two distinct genomic functional signatures purified human cells monocytes....